Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT04209530
Other study ID # EN3835-212
Secondary ID
Status Terminated
Phase Phase 2
First received
Last updated
Start date November 20, 2019
Est. completion date October 5, 2020

Study information

Verified date November 2020
Source Endo Pharmaceuticals
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a single center, open-label, Phase 2a study to assess the photonumeric scale, morphological, and histopathological changes associated with Collagenase Clostridium Histolyticum (CCH) in adult women with moderate or severe Edematous Fibrosclerotic Panniculopathy (EFP).


Recruitment information / eligibility

Status Terminated
Enrollment 7
Est. completion date October 5, 2020
Est. primary completion date July 23, 2020
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Female
Age group 18 Years to 50 Years
Eligibility Inclusion Criteria: 1. Have both buttocks or both posterolateral thighs with: 1. A score of 3 or 4 (moderate or severe) as reported by the investigator using the Clinician-Reported Photonumeric Cellulite Severity Scale (CR-PCSS). 2. A Hexsel Cellulite Severity Scale (CSS) Subsection A "Number of Evident Depressions" score of >0, and Subsection B "Depth of Depressions" score of 2 )medium depth depression) or 3 (deep depressions).. 2. Have a minimum of 2 well defined and isolated cellulite dimples. 3. Be willing to apply sunscreen to the treatment area before each exposure to the sun for the duration of the study (from the Screening Visit through the Day 251/Early Termination Visit). 4. Be judged to be in good health. 5. Have a negative pregnancy test. 6. Be willing and able to cooperate with the requirements of the study. Exclusion Criteria: 1. Is from a vulnerable population, as defined by the United States (US) Code of Federal Regulations (CFR) Title 45, Part 46, Section 46.111(b) and other local and national regulations, including but not limited to, employees (temporary, part-time, full time, etc) or a family member of the research staff conducting the study, or of the sponsor, or of the contract research organization, or of the Institutional Review Board (IRB)/Independent Ethics Committee (IEC). 2. Has a history of sensitivity or allergy to collagenase or any other excipient of CCH. 3. Has systemic conditions (coagulation disorders, malignancy, keloidal scar, abnormal wound healing) that restricts study participation. 4. Has local (in areas to be treated) conditions (thrombosis, vascular disorder, active infection/inflammation, active cutaneous alteration, tattoo/mole) that restricts study participation. 5. Has skin laxity or linear undulations on the treatment region (both buttocks or both thighs) that can be effaced by lifting skin. 6. Requires anticoagulant or antiplatelet medication during the study. 7. Has used or intends to use any of the local applications/therapies/injections/procedures that restricts study participation. 8. Has used any form of artificial tanning (sprays, lotions, tanning booth, etc) within the 30 days prior to the first dose of study treatment or plans to use any form of artificial tanning during the study (through the Day 251/Early Termination Visit). 9. Has a positive HIV test and/or a positive Hepatitis B surface antigen (HBsAg) or Hepatitis B core antibody (HBcAb) test at screening. 10. Has had any surgery, invasive procedure (eg, liposuction), injectable treatment (eg, KYBELLA®) or any similar treatment. 11. Has a history of keloids, hypertrophied scars, and/or other complications following biopsy. 12. Has any contraindications for MRI(implant containing metal, internal metallic object, permanent cosmetics/make-up, claustrophobia, syncope, low blood pressure, epilepsy, asthma, sickle cell disease) that restricts study participation. 13. Has received any collagenase treatments at any time prior to treatment in this study and/or has received EN3835 or CCH in a previous investigational study for cellulite. 14. Has previously received treatment with CCH in this clinical study. 15. Has received treatment with an investigational product within 30 days (or 5 half-lives, whichever is longer) of the Screening Visit. 16. Is pregnant and/or is providing breast milk or plans to become pregnant and/or to provide breast milk during the course of the study. 17. Has any other condition(s) that, in the investigator's opinion, might indicate the subject to be unsuitable for the study.

Study Design


Related Conditions & MeSH terms

  • Cellulite
  • Edematous Fibrosclerotic Panniculopathy (EFP)

Intervention

Drug:
EN3835
Collagenase Clostridium Histolyticum (CCH)

Locations

Country Name City State
United States Endo Clinical Trial Site #1 Coral Gables Florida

Sponsors (1)

Lead Sponsor Collaborator
Endo Pharmaceuticals

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary The Change From Baseline (Screening) in PR-PCSS Patient-Reported Photonumeric Cellulite Severity Scale (PR-PCSS) is a 5-point photonumeric scale rating cellulite severity from "0" (None) to "4" (Severe) from a patient's perspective Day 71
Secondary The Change From Baseline (Screening) in CR-PCSS Clinician-Reported Photonumeric Cellulite Severity Scale (CR-PCSS) is a 5-point photonumeric scale rating cellulite severity from "0" (None) to "4" (Severe) from a clinician's perspective Day 22, Day 43 and Day 71
Secondary The Change From Baseline (Screening) in Hexsel Cellulite Severity Scale (CSS) Hexsel CSS is a photonumeric scale that looks at 5 key morphologic features of cellulite, each feature is evaluated on a 4-point scale from "0" (Low) to "3" (High) Day 22, Day 43 and Day 71
Secondary MRI Before and After CCH Treatment Magnetic Resonance Imaging (MRI) of cellulite before and after CCH treatment Day 71
Secondary Histopathology Before and After CCH Treatment Histopathology of biopsies defined by the observation of the biopsied specimen by a trained Pathologist Day 71
See also
  Status Clinical Trial Phase
Completed NCT03550157 - Structural Changes of Subcutaneous Tissue by Ultrasonographies in Patients After Treatment With PnKCelulitis® Program
Completed NCT03078647 - Profound Dermal and SubQ Cartridges for the Treatment of Cellulite N/A
Suspended NCT05441917 - Phototherapy and Radiofrecuency for Cellulite N/A
Completed NCT02942160 - EN3835 for the Treatment of Edematous Fibrosclerotic Panniculopathy (Commonly Known as Cellulite) Phase 2
Active, not recruiting NCT02489994 - Performance of the ePrime System for Cellulite N/A
Completed NCT01209767 - Cryolipolysis and Subcision for Treatment of Cellulite N/A
Completed NCT01702259 - Study of the Effect of Low Level Laser Light Therapy on Reducing the Appearance of Cellulite in the Thighs and Buttocks. N/A
Completed NCT04580303 - CCH Treatment of Cellulite in the Presence of Dermal Laxity With Comparison Between Two (2) Different Injection Techniques Phase 2
Completed NCT05358847 - Treatment for Cellulite Appearance N/A
Completed NCT05064761 - Safety and Effectiveness of Poly-l-lactic Acid (PLLA) for the Improvement in Appearance of Cellulite N/A
Completed NCT03329989 - Safety and Effectiveness of EN3835 in the Treatment of EFP in Women Phase 2
Completed NCT04170296 - Real World CCH Study in Adult Females With Cellulite Phase 3
Completed NCT04419454 - Retrospective Evaluation of Cellulite of Laxity Treatment Using Body Tite
Completed NCT05199506 - Study to Evaluate the Safety and Effectiveness of the RAP Device for the Improvement in the Appearance of Cellulite N/A
Completed NCT05836779 - A Study to Evaluate the Efficacy and Safety of CBL-514 in Participants With EFP; Cellulite (Stage 2) Phase 2
Completed NCT05026216 - To Assess the Effectiveness of Multiple Dose, Multiple Concentrations of Qwo, for the Treatment of Mild to Moderate Cellulite. Phase 4
Completed NCT00399854 - Evaluation of the Efficacy of Endermologie in Treatment of Cellulite and Body Contouring Phase 4
Completed NCT00947414 - Cellulite and Extracorporeal Shock Wave N/A
Completed NCT05419505 - Study of Different Interventions to Reduce Bruising Following CCH-Aaes Treatment for Cellulite of the Buttocks Phase 2
Completed NCT03981198 - Proof of Concept (POC) Study of the Soliton Rapid Acoustic (RAP) for the Treatment of Cellulite N/A